BR100 Increased By (0.8%)
BR30 Increased By (0.86%)
KSE100 Increased By (0.8%)
KSE30 Increased By (0.87%)
AGHA 6.37 Decreased By ▼ -0.01 (-0.16%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.70 Increased By ▲ 0.15 (0.24%)
BOP 31.35 Decreased By ▼ -0.04 (-0.13%)
CNERGY 11.78 Increased By ▲ 0.05 (0.43%)
CSIL 5.75 Decreased By ▼ -0.16 (-2.71%)
FCCL 61.74 Increased By ▲ 0.03 (0.05%)
FFL 14.88 Increased By ▲ 0.09 (0.61%)
FNEL 1.28 Increased By ▲ 0.04 (3.23%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.85 Increased By ▲ 0.16 (0.65%)
MLCF 105.60 Increased By ▲ 1.67 (1.61%)
NBP 174.35 Increased By ▲ 1.03 (0.59%)
NCPL 52.50 Increased By ▲ 0.67 (1.29%)
NPL 54.95 Increased By ▲ 0.92 (1.7%)
OGDC 318.33 Increased By ▲ 2.46 (0.78%)
PACE 9.25 Decreased By ▼ -0.01 (-0.11%)
PAEL 35.83 Increased By ▲ 0.25 (0.7%)
PIBTL 14.14 Increased By ▲ 0.48 (3.51%)
PPL 229.20 Increased By ▲ 3.13 (1.38%)
PRL 81.30 Increased By ▲ 1.02 (1.27%)
PTC 46.82 Increased By ▲ 0.18 (0.39%)
SSGC 23.97 Increased By ▲ 0.15 (0.63%)
TBL 9.34 Increased By ▲ 0.10 (1.08%)
TELE 7.61 Increased By ▲ 0.06 (0.79%)
TPL 24.82 Increased By ▲ 0.28 (1.14%)
TPLP 12.96 Decreased By ▼ -0.03 (-0.23%)
TREET 27.16 Increased By ▲ 1.18 (4.54%)
TRG 54.00 Increased By ▲ 0.67 (1.26%)
World

China approves first domestic mRNA vaccine for Covid-19

Published Updated
By

BEIJING: China has approved its first locally developed messenger RNA (mRNA) vaccine against Covid-19, its manufacturer said Wednesday, months after the relaxation of strict Covid-zero regulations sparked a surge in cases.

The vaccine, developed by CSPC Pharmaceutical Group Ltd, has been approved for “emergency use” by Beijing’s health regulator, the company said in a statement.

It showed high efficacy in a trial in which it was used as a booster shot for people who have been given other types of vaccines, the company added, without offering further details.

China to reopen borders to foreign tourists for first time since 2020

mRNA vaccines are considered among the most effective in reducing severe infections and deaths.

While traditional vaccines use a weakened or inactivated germ to prepare the body for a future attack from the real virus, mRNA deploys snippets of genetic material that carry instructions showing the body’s cells how to produce a protein – in this case, the spike protein on the coronavirus that causes Covid.

The body’s immune system then triggers antibodies to fight off that spike protein, making it ready for when the real coronavirus comes knocking.

Beijing has refused to greenlight mRNA-based vaccines from foreign firms Pfizer-BioNTech and Moderna for public use.

Its vaccination shortfall was widely believed to have led to more severe infections and deaths after lockdowns and mandatory quarantine rules were suddenly dropped in December.

Other Chinese drugmakers including CanSino have previously said they were developing mRNA-based shots to help the country bridge its immunisation gap.

Comments

Comments are closed for this article.